Pharmacotherapy of social anxiety disorder

Current Topics in Behavioral Neurosciences

Volumn 2, Issue , 2010, Pages 487-503

  Ganasen, Keith A ^a   Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Controlled trials; Liebowitz Social Anxiety Scale; Medication; Meta analysis; Social anxiety disorder

Indexed keywords

ATENOLOL; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; BUSPIRONE; CLONAZEPAM; CYCLOSPORIN; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; PHENELZINE; PLACEBO; PREGABALIN; PROPRANOLOL; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ARTICLE; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; DEPRESSION; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RELAPSE; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; UNSTEADINESS; WEIGHT GAIN; XEROSTOMIA; CLINICAL TRIAL (TOPIC); PHOBIA; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; HUMANS; MONOAMINE OXIDASE INHIBITORS; PHOBIC DISORDERS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79952253795     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2009_1     Document Type: Article

References (78)

1. Aarre TF (2003) Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord J Psychiatry 57:313-315
2. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G (2004) Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 19:387-396
3. Asakura S, Tajima O, Koyama T (2007) Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 10:263-274
4. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU, British Association for Psychopharmacology (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596
5. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HG (1998) Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59:54-60
6. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ (2008) World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 9:248-312
7. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR (2002) Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 16:365-368
8. Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl 1989:21-31
9. Blanco C, Raza MS, Schneier FR, Liebowitz MR (2003) The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 6:427-442
10. Clark DB, Agras WS (1991) The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 148:598-605
11. Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS (2001) Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 40:564-571
12. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH (1993) Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13:423-428
13. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM (2004) Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social anxiety disorder. Arch Gen Psychiatry 61:1005-1013
14. Davis M, Ressler K, Rothbaum BO, Richardson R (2006) Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 60:369-375
15. Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U (1995) Social anxiety disorder: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand 92:351-358
16. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M (2002) Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42:229-236
17. Foa EB, Franklin ME, Moser J (2002) Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry 52:987-997
18. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, Fredrikson M (2002) Common changes in cerebral blood flow in patients with social anxiety disorder treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 59:425-433
19. Furmark T, Tillfors M, Garpenstrand H, Marteinsdottir I, Langstrom B, Oreland L, Fredrikson M (2004) Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social anxiety disorder. Neurosci Lett 362:189-192
20. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ (1991) Cognitive-behavioral and pharmacological treatments of social anxiety disorder. A controlled study. Arch Gen Psychiatry 48:938-945
21. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR (2008) A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 63:544-549
22. Hartley LR, Ungapen S, Davie I, Spencer DJ (1983) The effect of beta adrenergic blocking drugs on speakers' performance and memory. Br J Psychiatry 142:512-517
23. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW (2006) Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63:298-304
24. Ipser JC, Kariuki CM, Stein DJ (2008) Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 8:235-257
25. Isolan L, Pheula G, Salum GA Jr, Oswald S, Rohde LA, Manfro GG (2007) An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol 17:751-760
26. James IM, Burgoyne W, Savage IT (1983) Effect of pindolol on stress-related disturbances of musical performance: preliminary communication. J R Soc Med 76:194-196
27. Kasper S, Stein DJ, Loft H, Nil R (2005) Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222-226
28. Katschnig H (1997) The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social anxiety disorder. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 247:71-80
29. Kelly D (1973) Phenelzine in phobic states. Proc R Soc Med 66:949-950
30. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ (2002) Fluoxetine in social anxiety disorder: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 22:257-262
31. Lader M, Stender K, Burger V, Nil R (2004) Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19:241-248
32. Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L (2004) Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 65:222-229
33. Liebowitz MR, Gorman JM, Fyer AJ, Klein DF (1985) Social anxiety disorder. Review of a neglected anxiety disorder. Arch Gen Psychiatry 42:729-736
34. Liebowitz MR, Schneier F, Campeas R, Gorman J, Fyer A, Hollander E, Hatterer J, Papp L (1990) Phenelzine and atenolol in social anxiety disorder. Psychopharmacol Bull 26:123-125
35. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R (1992) Phenelzine vs atenolol in social anxiety disorder. A placebo-controlled comparison. Arch Gen Psychiatry 49:290-300
36. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, Goetz D, Juster HR, Lin SH, Bruch MA, Marshall RD, Klein DF (1999) Cognitive-behavioral group therapy versus phenelzine in social anxiety disorder: long-term outcome. Depress Anxiety 10:89-98
37. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD (2002) A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63:66-74
38. Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM (2003) Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64:785-792
39. Liebowitz MR, Gelenberg AJ, Munjack D (2005a) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62:190-198
40. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G (2005b) A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238-247
41. Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC (1997) Brofaromine for social anxiety disorder: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 17:255-260
42. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP (2005) A 24-week randomized, doubleblind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270-1278
43. Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa GF, Leiberich PK, Rother N, Bachler E, Fartacek R, Kaplan P, Tritt K, Mitterlehner F, Anvar J, Rother WK, Loew TH, Egger C (2005) Mirtazapine treatment of social anxiety disorder in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 25:580-583
44. Noyes R Jr, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain JW, Curlik SM, Kent TA, Lydiard RB, Mallinger AG, Pollack MH, Rapaport M, Rasmussen SA, Hedges D, Schweizer E, Uhlenhuth EH (1997) Moclobemide in social anxiety disorder: a controlled dose-response trial. J Clin Psychopharmacol 17:247-254
45. Pallanti S, Quercioli L (2006) Resistant social anxiety disorder response to Escitalopram. Clin Pract Epidemol Ment Health 2:35 Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH,
46. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM (1999) Treatment of social anxiety disorder with gabapentin: a placebocontrolled study. J Clin Psychopharmacol 19:341-348
47. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24:141-149
48. Prasko J, Dockery C, Horacek J, Houbova P, Kosova J, Klaschka J, Paskova B, Praskova H, Seifertova D, Zalesky R, Hoschl C (2006) Moclobemide and cognitive behavioral therapy in the treatment of social anxiety disorder. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett 27:473-481
49. Rodebaugh TL, Holaway RM, Heimberg RG (2004) The treatment of social anxiety disorder. Clin Psychol Rev 24:883-908
50. Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplan J, Liebowitz MR (1993) Buspirone in social anxiety disorder. J Clin Psychopharmacol 13:251-256
51. Seedat S, Stein MB (2004) Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 65:244-248
52. Segool NK, Carlson JS (2008) Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety 25:620-631
53. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH (2006) An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381-385
54. Stein MB, Stein DJ (2008) Social anxiety disorder. Lancet 371:1115-1125
55. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B (1999) Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156:756-760
56. Stein MB, Sareen J, Hami S, Chao J (2001) Pindolol potentiation of paroxetine for generalized social anxiety disorder: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158:1725-1727
57. Stein DJ, Cameron A, Amrein R, Montgomery SA (2002a) Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 17:161-170
58. Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B (2002b) Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 63:152-155
59. Stein DJ, Versiani M, Hair T, Kumar R (2002c) Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 59:1111-1118
60. Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM (2003) Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12-to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 6:317-323
61. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 177:280-288
62. Stein MB, Seedat S, Gelernter J (2006) Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 187:68-72
63. Swinson RP, Antony MM, Bleau PB, Chokka P, Craven M, Fallu A et al (2006) Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry 51(S2):1-92
64. Tyrer P, Candy J, Kelly D (2003) Phenelzine in phobic anxiety: a controlled trial. Psychol Med 3:120-124
65. Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR (2007) Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 31:1464-1469
66. Van Ameringen M, Mancini C, Wilson C (1996) Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social anxiety disorder. J Affect Disord 39:115-121
67. Van Ameringen M, Mancini C, Oakman J, Walker J, Kjernisted K, Chokka P, Johnston D, Bennett M, Patterson B (2007) Nefazodone in the treatment of generalized social anxiety disorder: a randomized, placebo-controlled trial. J Clin Psychiatry 68:288-295
68. Van Vliet IM, den Boer JA, Westenberg HG (1994) Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 115:128-134
69. Van Vliet IM, den Boer JA, Westenberg HG, Pian KL (1997) Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 58:164-168
70. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R (1992) Pharmacotherapy of social anxiety disorder. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353-360
71. Versiani M, Nardi AE, Figueira I, Mendlowicz M, Marques C (1997) Double-blind placebo controlled trial with bromazepam in social anxiety disorder. J Bras Psiquiatr 3:167-171
72. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A (2004) A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61:1153-1162
73. Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, Johnston DC, Lavallie YJ, Nandy S, Pecknold JC, Hadrava V, Lane RM (2000) Prevention of relapse in generalized social anxiety disorder: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 20:636-644
74. Walkup JT, Labellarte MJ, Riddle MA et al (2001) Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 344:1279-1285
75. Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC (2008) Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 359:2753-2766
76. Warwick JM, Carey P, van der Linden G, Prinsloo C, Niehaus D, Seedat S, Dupont P, Stein DJ (2006) A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder. Metab Brain Dis 21:241-252
77. Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM (2004) A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:49-55
78. Zhang W, Connor KM, Davidson JR (2005) Levetiracetam in social anxiety disorder: a placebo controlled pilot study. J Psychopharmacol 19:551-553